|
Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction. |
|
|
Honoraria - Celgene; Isis Pharmaceuticals; Med Learning Group; Millennium; Novartis; Onyx; Research to Practice; Sanofi |
|
|
|
Consulting or Advisory Role - Onyx; Prothena; Spectrum Pharmaceuticals |
Research Funding - Onyx; Takeda |
|
|
Consulting or Advisory Role - Janssen; Takeda |
Research Funding - Janssen; Prothena; Takeda; Teva |
Patents, Royalties, Other Intellectual Property - Not licensed yet |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Janssen; Millennium |
Research Funding - Janssen; Onclave Therapeutics |
|
|
|
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Celgene; Prothena |
Research Funding - Celgene |
Other Relationship - Pharmacyclics |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Multiple, including Prothena Biosciences |
Consulting or Advisory Role - Janssen |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb, Merck, Elan, Prothena Biosciences |
|
|
|
|
Stock and Other Ownership Interests - Prothena |
Travel, Accommodations, Expenses - Prothena |
|
|
Consulting or Advisory Role - Amgen |
Research Funding - Celgene; Onyx; Pfizer; Prothena; Takeda |